Health
Partnership to develop head and neck cancer vaccine – Mirage News
Professor Christian Ottensmeier (centre)Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company)…
Professor Christian Ottensmeier (centre)
Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company) have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the UK die each year. Whilst exis…
-
General15 hours ago‘We are here for you’: PM to bring help to flood zones
-
General14 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News22 hours agoStudents say new facility would be better in rural areas of Queensland
-
Business12 hours ago10 ASX shares to buy after the market selloff